FeesSafety
Pluang+

Norsk Hydro posts strong Q2 2026 with 6% revenue growth and 15% EBITDA rise, leading in low-carbon aluminum.

Market News
24 Jul 2026, 05:54 WIB
Seeking Alpha
View Source
Bullish
Norsk Hydro posts strong Q2 2026 with 6% revenue growth and 15% EBITDA rise, leading in low-carbon aluminum.

Norsk Hydro reported solid Q2 2026 results, with revenue up 6% to NOK 56.49 billion and adjusted EBITDA rising 15% to NOK 8.92 billion. The company is transforming into a vertically integrated, low-carbon aluminum leader, leveraging renewable energy and recycling assets. Hydro benefits from European aluminum scarcity, regional premiums, and long-term power contracts, supporting disciplined capacity expansion. Despite strong fundamentals and strategic positioning for low-carbon demand, Norsk Hydro trades at a valuation discount, suggesting potential upside for investors.

More News

NVIDIA Board launches probe into CEO Jensen Huang over foreign intelligence concerns.

NVIDIA Board launches probe into CEO Jensen Huang over foreign intelligence concerns.

NVIDIA's Board of Directors has started an independent investigation after reports that CEO Jensen Huang was targeted by a foreign intelligence operation. The inquiry, led by independent directors and external counsel, aims to ensure no national secu...

Market News
Neutral
18 minutes ago
Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
4 hours ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
4 hours ago
Lawsuit probes J.B. Hunt for allegedly misleading investors after Q3 earnings warning

Lawsuit probes J.B. Hunt for allegedly misleading investors after Q3 earnings warning

Rosen Law Firm is investigating J.B. Hunt Transport Services for possibly providing misleading business information to investors after the company warned of a Q3 earnings decline. The firm's shares dropped sharply following a CNBC report about increa...

Market News
Bearish
5 hours ago
Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

Others
Neutral
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App